Expert Reaction: U.S. FDA Approves Roflumilast Foam 0.3% (Zoryve, Arcutis) for Plaque Psoriasis of the Scalp and Body
Jennifer Soung, MD, discusses what the FDA’s approval of roflumilast foam means for psoriasis patients and their providers.
Category: Headlines in Dermatology